Insider Trading June 26, 2026 07:03 PM

Atlanticus CEO Howard Offloads $1.09M in Shares Amid Strong Stock Performance

Executive reduction in position occurs as ATLC approaches 52-week highs, with recent earnings showing mixed results.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ATLC

Jeffrey A. Howard, President and CEO of Atlanticus Holdings Corp (NASDAQ:ATLC), executed a significant stock sale on June 26, 2026, divesting 10,000 shares worth $1,094,500. The transaction, priced between $107.87 and $110.98 with a weighted average of $109.45 per share, leaves Howard with a direct holding of 673,265 shares. This move coincides with ATLC trading near its 52-week high of $112.61, following a 112% return over the past year. While the stock appears overvalued relative to its Fair Value according to InvestingPro analysis, the company recently reported Q1 2026 earnings that beat EPS expectations but missed revenue targets. Analyst ratings remain mixed, with Texas Capital Securities initiating a Hold rating and Citizens maintaining a Market Outperform rating. Additionally, Atlanticus Holdings elected seven new directors at its Annual Meeting of Shareholders, with terms expiring in 2027.

Atlanticus CEO Howard Offloads $1.09M in Shares Amid Strong Stock Performance
ATLC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Jeffrey Howard sold 10,000 shares worth $1,094,500 on June 26, 2026, reducing his direct stake in Atlanticus Holdings.
  • ATLC stock approaches 52-week high of $112.61 after a 112% annual return, though it appears overvalued relative to Fair Value.
  • Q1 2026 earnings showed strong EPS of $2.23 but missed revenue expectations, with analyst ratings split between Hold and Market Outperform.

Jeffrey A. Howard, serving as both President and Chief Executive Officer of Atlanticus Holdings Corp (NASDAQ:ATLC), completed a transaction on June 26, 2026, involving the sale of 10,000 shares of the company's common stock. The total value of this divestment reached $1,094,500. The shares were liquidated at prices varying between $107.87 and $110.98, resulting in a weighted average sale price of $109.45 per share. Post-transaction, Howard maintains a direct ownership stake of 673,265 shares in Atlanticus Holdings.


The timing of this sale is notable as ATLC trades close to its 52-week high of $112.61. The stock has experienced a substantial 112% return over the preceding year. According to InvestingPro analysis, the equity currently appears overvalued when compared to its Fair Value metric. This valuation context may offer insight into the executive's decision to reduce his personal position in the company.


In broader corporate developments, Atlanticus Holdings Corporation released its Q1 2026 earnings results. The company reported an earnings per share (EPS) of $2.23, surpassing analyst expectations of $1.74 by a margin of 28.16%. However, revenue figures fell short of projections, coming in at $679.5 million against anticipated estimates of $749.25 million, marking a revenue surprise of -9.31%.


Analyst coverage for Atlanticus Holdings presents a mixed outlook. Texas Capital Securities initiated a Hold rating on the stock, setting a price target of $100, which implies a potential 12% upside. Conversely, Citizens maintained a Market Outperform rating with a $102 price target, citing potential gains from the Mercury acquisition.


Additionally, Atlanticus Holdings announced the election of seven directors during its recent Annual Meeting of Shareholders. These directors, including Brinkley Dickerson, David G. Hanna, and Denise M. Harrod, among others, have terms set to expire in 2027. These developments highlight ongoing strategic and operational activities within the organization.

Risks

  • The stock's overvaluation relative to Fair Value may indicate potential downside risk if market conditions shift.
  • Revenue miss in Q1 2026 could signal challenges in top-line growth, impacting investor confidence in the company's operational performance.
  • Mixed analyst ratings suggest uncertainty regarding the stock's near-term trajectory, with price targets ranging from $100 to $102.

More from Insider Trading

Personalis CFO Tachibana Executes $675K Stock Sale Under Pre-Approved Plan Jun 26, 2026 Slide Insurance Director Andrew Wright Executes Pre-Arranged Stock Sales Jun 26, 2026 Immunovant CTO Jay Stout Offloads $1.53M in Stock Ahead of Analyst Upgrades Jun 26, 2026 Personalis CEO Christopher Hall Executes $1.31M Stock Sale Under Pre-Arranged Plan Jun 26, 2026 Immunovant Executive Trims Holdings as Stock Nears Peak Valuation Jun 26, 2026